{"id":40005,"date":"2026-08-10T06:54:41","date_gmt":"2026-08-10T06:54:41","guid":{"rendered":"https:\/\/mdfl-blog20.azurewebsites.net\/blog\/?p=40005"},"modified":"2026-08-10T06:56:41","modified_gmt":"2026-08-10T06:56:41","slug":"glp-1-therapy-in-obesity-care","status":"publish","type":"post","link":"https:\/\/mdforlives.com\/blog\/endocrinology-and-metabolic-health\/glp-1-therapy-in-obesity-care\/","title":{"rendered":"GLP-1 Therapy in Obesity Care: Why Staying on Treatment Is the Real Test"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A GLP-1 prescription can begin with clinical confidence and still end in uncertainty.<\/span>\u00a0<\/span><\/p>

That is the tension now shaping obesity care. The question is no longer only whether GLP-1 and GLP-1\/GIP therapies can support meaningful weight loss. The more\u00a0difficult question\u00a0is whether patients can stay on them long enough for that benefit to translate into durable care.<\/span>\u00a0<\/span><\/p>

Globally, obesity is increasingly being treated as a chronic, relapsing condition rather than a short-term lifestyle problem. The World Health Organization\u2019s 2025 guidance on GLP-1 therapies for obesity reinforces this shift, positioning treatment within a broader model that includes long-term care, healthy diets, physical activity, clinical support, affordability, and health-system readiness [WHO, 2025]. A large real-world cohort study published in JAMA Network Open also showed why continuity matters: among adults with overweight or obesity starting GLP-1 receptor agonists, discontinuation within one year was common, especially among patients without type 2 diabetes [JAMA Network Open, 2025].<\/span>\u00a0<\/span><\/p>

Against this backdrop,\u00a0MDForLives\u00a0clinician-reported research across the USA, UK, Canada, France, Germany, and Italy reveals a clear pattern. GLP-1 therapy has crossed the belief threshold in obesity care. It has not yet crossed the delivery threshold.<\/span><\/p>

Clinicians Are No Longer Questioning Relevance<\/span><\/span>\u00a0<\/span><\/strong><\/h2>

More than 90% of clinicians in the\u00a0<\/span>MDForLives<\/span>\u00a0research described GLP-1 or GLP-1\/GIP therapies as highly or moderately relevant to obesity management, with\u00a0<\/span>nearly three-quarters<\/span>\u00a0rating them as highly relevant.<\/span><\/p>

That level of agreement signals a meaningful change. GLP-1 therapy is no longer being viewed as a niche or experimental\u00a0option. <\/span><\/p>

The shift reflects a wider trend toward evidence-based metabolic interventions, including areas of investigation such as growth hormone therapy<\/a> for obesity-related metabolic conditions.<\/p><\/blockquote>

It has entered the clinical decision-making framework for obesity care.<\/span>\u00a0<\/span><\/p>

But relevance is\u00a0not the same as\u00a0readiness. Clinicians may believe in the therapy and still hesitate if continuation feels uncertain. This is where the insight becomes sharper: the barrier is not clinical acceptance. It is practical confidence.<\/span><\/p>

Routine Use Depends on the System Around the Therapy<\/span><\/span>\u00a0<\/span><\/strong><\/h2>

At an overall level, around two-thirds of clinicians said they routinely consider GLP-1 therapy for obesity independent of diabetes, while another quarter\u00a0consider\u00a0it occasionally.<\/span>\u00a0<\/span><\/p>

On the surface, this suggests strong adoption. But country-level differences reveal how deeply system design shapes prescribing behavior. In the USA, more than 80% of clinicians reported routine consideration. In the UK, fewer than 40% described GLP-1 therapy as routine.<\/span>\u00a0<\/span><\/p>

This gap does not necessarily reflect a difference in clinical belief. It reflects different access pathways, funding structures, prescribing controls, and service capacity. NICE guidance and NHS England\u2019s phased commissioning approach for tirzepatide show how obesity pharmacotherapy access may depend on eligibility criteria,\u00a0prioritised\u00a0cohorts, and implementation capacity [NICE, 2024; NHS England, 2026].<\/span>\u00a0<\/span><\/p>

For clinicians, this means adoption is filtered through system feasibility. A therapy may be\u00a0appropriate, but access rules decide how often it becomes a real\u00a0option.<\/span><\/p>

These access considerations also influence decisions around other obesity interventions, including bariatric surgery for weight loss<\/a>, where eligibility criteria, affordability, and long-term follow-up requirements can affect treatment uptake.<\/p><\/blockquote>

Real-World Outcomes Are Trusted, But Not Taken for Granted<\/span><\/span><\/strong><\/h2>

\"clinical<\/p>

Clinician\u00a0confidence in GLP-1 outcomes\u00a0remains\u00a0strong, but it is not absolute.\u00a0More than 80% of respondents said real-world weight loss outcomes are aligned with clinical trial expectations.\u00a0Yet only 18% described outcomes as closely aligned, while 66% said they were only\u00a0somewhat aligned. Around 15% reported outcomes as often lower than expected or highly variable.<\/span>\u00a0<\/span><\/p>

This does not suggest that clinicians doubt GLP-1 therapy. Rather, it shows that real-world care introduces variables that trials cannot fully\u00a0contain.<\/span>\u00a0<\/span><\/p>

Treatment may be interrupted. Titration may be delayed.\u00a0Coverage\u00a0may change. Side effects may affect persistence. Patients may lose motivation if expectations were not clearly set from the beginning.<\/span>\u00a0<\/span><\/p>

In other words, efficacy may be trusted, but durability is not assumed.<\/span><\/p>

Suitability Is Becoming a Question of Feasibility<\/span><\/span>\u00a0<\/span><\/strong><\/h2>

Clinical eligibility and comorbidities\u00a0remain\u00a0the leading factor in patient selection, cited by 52% of clinicians. But 32% now\u00a0identify\u00a0expected adherence and patient motivation as the most\u00a0important factor.<\/span>\u00a0<\/span><\/p>

This is a quiet but important shift in obesity care. Clinicians are not only asking, \u201cIs this patient clinically eligible?\u201d They are also asking, \u201cCan this patient realistically continue therapy?\u201d<\/span>\u00a0<\/span><\/p>

These considerations can be especially important for patients living with PCOS<\/a>, where treatment adherence and long-term metabolic outcomes are often closely linked.<\/p><\/blockquote>

Cost and coverage were cited directly by a smaller share of clinicians, but their indirect influence is much wider. If affordability or reimbursement is unstable, clinicians may become cautious even before treatment begins.<\/span>\u00a0<\/span><\/p>

The uncomfortable implication is that some patients may not start GLP-1 therapy despite being clinically suitable. Not because the therapy is inappropriate, but because continuation feels fragile from the outset.<\/span>\u00a0<\/span><\/p>

Discontinuation Is Often Financial Before It Is Clinical<\/strong><\/h2>

When clinicians were asked what most commonly limits long-term continuation, more than half pointed to cost or loss of coverage. Gastrointestinal side effects accounted for 28%, while adherence and clinical reassessment formed smaller shares.<\/span>\u00a0<\/span><\/p>

This matters because it\u00a0reframes\u00a0the real-world challenge. Side effects are important, but they are not the dominant continuation barrier in the\u00a0MDForLives\u00a0findings. Affordability is.<\/span>\u00a0<\/span><\/p>

In the USA, this pattern appears especially strong, with\u00a0nearly 70%\u00a0of clinicians citing financial disruption as the leading reason for discontinuation. In the UK, the picture is more distributed, with service pathways, review processes, and prescribing limitations playing a more visible role.<\/span>\u00a0<\/span><\/p>

For clinicians, stopping\u00a0a therapy\u00a0because it is not working is one thing. Stopping a therapy that may be working because access collapses\u00a0is\u00a0different. That experience can influence future prescribing conversations and make clinicians more guarded when starting treatment.<\/span>\u00a0<\/span><\/p>

Patient Expectations May Be the Most Underestimated Risk\u00a0<\/strong><\/h2>

Only about one-quarter of clinicians believe patients\u00a0generally understand\u00a0the long-term nature of GLP-1 therapy.\u00a0More than half describe patient understanding as partial, and more than 20% say expectations are often misunderstood.<\/span>\u00a0<\/span><\/p>

This is not a small communication gap. It affects adherence, persistence, and trust.<\/span>\u00a0<\/span><\/p>

Patients may approach GLP-1\u00a0therapy\u00a0expecting rapid weight loss or short-term treatment. <\/span><\/p>

Much like individuals living with diabetes<\/a>, patients with obesity often achieve better outcomes when they understand that long-term disease management requires sustained engagement and realistic expectations.<\/p><\/blockquote>

Clinicians, however, are increasingly framing obesity as a chronic condition requiring sustained management. When those two expectations are misaligned, the treatment journey becomes vulnerable.<\/span>\u00a0<\/span><\/p>

If access barriers arise, if side effects appear, or if progress slows, patients who were not prepared for long-term care may be more likely to stop.<\/span>\u00a0<\/span><\/p>

This makes expectation-setting a clinical intervention in itself.<\/span>\u00a0<\/span><\/p>

The Future Impact of GLP-1 Therapy Will Be Decided Beyond the Prescription\u00a0<\/strong><\/h2>

\"GLP-1<\/p>

When clinicians looked ahead,\u00a0nearly 65%\u00a0identified\u00a0expanded coverage and affordability as the most\u00a0important factor\u00a0shaping the future impact of GLP-1 therapy in obesity care. Another 18% pointed to better long-term adherence strategies.<\/span>\u00a0<\/span><\/p>

Clearer guidance and stronger real-world evidence were less\u00a0frequently\u00a0selected.<\/span>\u00a0<\/span><\/p>

That finding is telling. For many clinicians, the scientific case is already strong enough. The unresolved question is whether healthcare systems can support sustained use fairly, predictably, and at scale.<\/span>\u00a0<\/span><\/p>

This is where GLP-1 therapy now sits: clinically effective, increasingly accepted, but operationally fragile.<\/span>\u00a0<\/span><\/p>

Closing Perspective\u00a0<\/strong><\/h2>

GLP-1 therapy\u00a0represents\u00a0one of the most important advances in obesity care in recent years. It has changed how clinicians think about pharmacologic weight management and strengthened the case for treating obesity as a chronic condition.<\/span>\u00a0<\/span><\/p>

But the\u00a0MDForLives\u00a0findings suggest that real-world impact will depend less on whether clinicians believe in GLP-1 therapy and more on whether patients can stay on it.<\/span>\u00a0<\/span><\/p>

The next phase of obesity care will not be defined by initiation alone. It will be defined by continuity.<\/span>\u00a0<\/span><\/p>

Until access frameworks, affordability, patient expectations, and long-term care pathways catch up with clinical confidence, GLP-1 therapy will remain caught between strong therapeutic promise and uneven real-world delivery.<\/span>\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

FAQs<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
Why is GLP-1 continuation important in obesity care? <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/i><\/span>\n\t\t\t<\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

GLP-1 therapy is\u00a0generally used\u00a0as part of long-term obesity management. If treatment is interrupted early, patients may not achieve or\u00a0maintain\u00a0the expected clinical benefit.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t
What are the main barriers to GLP-1 continuation? <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/i><\/span>\n\t\t\t<\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In the\u00a0MDForLives\u00a0clinician-reported research, cost or loss of coverage was the\u00a0most commonly cited\u00a0barrier to long-term continuation, followed by gastrointestinal side effects.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t
Are GLP-1 therapies considered relevant for obesity treatment without diabetes? <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/i><\/span>\n\t\t\t<\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Yes. More than 90% of clinicians in the\u00a0MDForLives\u00a0research described GLP-1 or GLP-1\/GIP therapies as highly or moderately relevant to obesity management.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t
Why do GLP-1 outcomes differ between clinical trials and real-world care? <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/i><\/span>\n\t\t\t<\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Real-world outcomes may be affected by delayed titration, access interruptions, cost barriers, side effects, adherence challenges, and differences in patient support.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t
What will shape the future of GLP-1 therapy in obesity care? <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/i><\/span>\n\t\t\t<\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Clinicians in the\u00a0MDForLives\u00a0research most often\u00a0identified\u00a0expanded coverage and affordability as the key factor that will influence future real-world impact.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t